CSL Ltd. ADR | |
Stock Exchange | Other OTC |
EPS |
$1.98 |
Market Cap |
$71.15 B |
Shares Outstanding |
906.28 M |
Public Float |
- |
CSL Ltd. | |
Stock Exchange | Other OTC |
EPS |
$3.97 |
Market Cap |
$71.72 B |
Shares Outstanding |
452.68 M |
Public Float |
- |
CSL Ltd. | |
Stock Exchange | Australian Stock Exchange |
EPS |
AUD5.37 |
Market Cap |
AUD101.8 B |
Shares Outstanding |
453.14 M |
Public Float |
451.15 M |
CSL Ltd. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
452.68 M |
Public Float |
- |
Address |
45 Poplar Road Parkville Victoria (VIC) 3052 Australia |
Employees | - |
Website | http://www.csl.com.au |
Updated | 07/08/2019 |
CSL Ltd. is a biopharmaceutical company, which engages in the research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. It operates through the CSL Behring and Seqirus segments. The CSL Behring segment provides plasma-derived and recombinant products, and operates plasma collection networks through CSL Plasma. |